JP2008533090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533090A5 JP2008533090A5 JP2008501286A JP2008501286A JP2008533090A5 JP 2008533090 A5 JP2008533090 A5 JP 2008533090A5 JP 2008501286 A JP2008501286 A JP 2008501286A JP 2008501286 A JP2008501286 A JP 2008501286A JP 2008533090 A5 JP2008533090 A5 JP 2008533090A5
- Authority
- JP
- Japan
- Prior art keywords
- cox
- class
- combination
- diseases
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 16
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 16
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 5
- 101150098694 PDE5A gene Proteins 0.000 claims 5
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- -1 Firokokishibu Chemical compound 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 229950010851 cimicoxib Drugs 0.000 claims 1
- KYXDNECMRLFQMZ-UHFFFAOYSA-N cimicoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=C(Cl)N=CN1C1=CC=C(S(N)(=O)=O)C=C1 KYXDNECMRLFQMZ-UHFFFAOYSA-N 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 229960000994 lumiracoxib Drugs 0.000 claims 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 229960000835 tadalafil Drugs 0.000 claims 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 229960002381 vardenafil Drugs 0.000 claims 1
Claims (12)
- 内在性のＰＤＥ５阻害成分を有するＣＯＸ−２選択的なＮＳＡＩＤ類のクラスからの、コキシブのクラスからの化合物を、ＣＯＸ−２選択的なＮＳＡＩＤ類の治療的使用と関連する心血管疾病の防止において使用するための医薬組成物の製造において用いる使用。
- 内在性のＰＤＥ５阻害成分を有するＣＯＸ−２選択的なＮＳＡＩＤ類のクラスからの、コキシブのクラスからの化合物を、ＣＯＸ−２阻害に反応を示す疾病の治療又は予防において、心血管疾病の危険性のある患者群で、心筋梗塞及び卒中発作の危険性が高い患者群で、浮腫、高血圧、異常脂肪血症、既存の心血管疾病及び／又は心不全を伴う患者で使用するための医薬組成物の製造において用いる使用。
- 内在性のＰＤＥ５阻害成分を有するＣＯＸ−２選択的なＮＳＡＩＤ類のクラスからの、コキシブのクラスからの化合物を、ＣＯＸ−２阻害に反応を示す疾病の長期の及び／又は高用量の治療又は予防において使用するための医薬組成物の製造において用いる使用。
- 内在性のＰＤＥ５阻害成分を有するＣＯＸ−２選択的なＮＳＡＩＤ類のクラスからの、コキシブのクラスからの化合物を、ＣＯＸ−２阻害に反応を示す疾病の治療又は予防をする一方で、心血管疾病の危険性を低下させるのに使用するための医薬組成物の製造において用いる使用。
- 請求項１から４までのいずれか１項記載の使用であって、内在性のＰＤＥ５阻害成分を有するＣＯＸ−２選択的なＮＳＡＩＤ類のクラスからの化合物が、セレコキシブである使用。
- 少なくとも１種のＣＯＸ−２選択的なＮＳＡＩＤ類のクラスからの、コキシブのクラスからの化合物である第一の有効成分と、少なくとも１種のＰＤＥ５インヒビターである第二の有効成分とを含有し、ＣＯＸ−２阻害に反応を示す疾病の治療又は予防において、別々に、連続的に、同時に又は時間的にずらして使用するための組合せ物。
- 請求項６記載の組合せ物を、ＣＯＸ−２阻害に反応を示す疾病の治療又は予防をする一方で、ＣＯＸ−２選択的なＮＳＡＩＤ類の単独での使用と関連する心血管疾病から保護するための医薬製品の製造において用いる使用。
- 請求項６から７までのいずれか１項記載の使用又は組合せ物であって、ＣＯＸ−２選択的なＮＳＡＩＤ類のクラスからの化合物が、セレコキシブ、シミコキシブ、エトリコキシブ、フィロコキシブ、ルミラコキシブ、パレコキシブ、ロフェコキシブ、チルマコキシブ及びバルデコキシブから選択される使用又は組合せ物。
- ＰＤＥ５インヒビターを、ＣＯＸ−２選択的なＮＳＡＩＤの単独での使用と関連する心血管疾病の防止のための医薬製品の製造において用いる使用。
- 請求項６から９までのいずれか１項記載の使用又は組合せ物であって、ＰＤＥ５インヒビターが、シルデナフィル、タダラフィル及びバルデナフィルから選択される使用又は組合せ物。
- 請求項１から１０までのいずれか１項記載の使用又は組合せ物であって、ＣＯＸ−２阻害に反応を示す疾病が、慢性炎症性疾病、リウマチ様関節炎を含むあらゆる種類の関節炎又は骨関節炎を含む変形性関節症；退行性痴呆、アルツハイマー病；及び一定の癌性もしくは前癌性の疾病、結腸直腸の腺腫もしくはポリープから選択される使用又は組合せ物。
- 請求項１から１１までのいずれか１項記載の使用であって、心血管疾病が、心血管性又は血栓塞栓性の有害事象、心筋梗塞又は脳血管事故、心臓発作又は卒中発作である使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65979105P | 2005-03-14 | 2005-03-14 | |
| EP05101977 | 2005-03-14 | ||
| PCT/EP2006/060686 WO2006097459A1 (en) | 2005-03-14 | 2006-03-14 | Method for preventing cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008533090A JP2008533090A (ja) | 2008-08-21 |
| JP2008533090A5 true JP2008533090A5 (ja) | 2009-04-30 |
Family
ID=35149314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501286A Withdrawn JP2008533090A (ja) | 2005-03-14 | 2006-03-14 | 心血管疾患の防止方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080171746A1 (ja) |
| EP (1) | EP1865951A1 (ja) |
| JP (1) | JP2008533090A (ja) |
| AU (1) | AU2006224623A1 (ja) |
| CA (1) | CA2600822A1 (ja) |
| WO (1) | WO2006097459A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8592400B2 (en) * | 2009-02-27 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Drug combinations containing PDE4 inhibitors and NSAIDs |
| JP2012519160A (ja) * | 2009-02-27 | 2012-08-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する組み合わせ薬 |
| WO2013036403A1 (en) * | 2011-09-06 | 2013-03-14 | Curna, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| WO2019157560A1 (en) * | 2018-02-16 | 2019-08-22 | Proteobioactives Pty Limited | Methods and compositions for the treatment of pain and/or inflammation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5777676A (en) * | 1980-10-31 | 1982-05-15 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| JP4979157B2 (ja) * | 1998-09-09 | 2012-07-18 | バイオリポックス アーべー | 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用 |
| US20020009764A1 (en) * | 1999-10-08 | 2002-01-24 | W. Joseph Thompson | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds |
| CN1216869C (zh) * | 1999-12-08 | 2005-08-31 | 药品公司 | 赛利可喜的多态晶型 |
| FR2809623B1 (fr) * | 2000-06-05 | 2003-09-05 | Sanjuan Benito Arranz | Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives) |
| PL366406A1 (en) * | 2001-04-19 | 2005-01-24 | Warner-Lambert Company Llc | Fused bicyclic or tricyclic amino acids |
| AU2002250756A1 (en) * | 2001-04-19 | 2002-11-05 | Universite De Montreal | A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress |
| PL210463B1 (pl) * | 2001-09-19 | 2012-01-31 | Nycomed Gmbh | Zastosowanie kombinacji roflumilastu z diklofenakiem w leczeniu zapalnych chorób stawów |
| US7091207B2 (en) * | 2002-05-22 | 2006-08-15 | Virginia Commonwealth University | Method of treating myocardial infarction with PDE-5 inhibitors |
| US20040048910A1 (en) * | 2002-08-22 | 2004-03-11 | Bove Susan Elizabeth | Method of treating osteoarthritis |
| EP1658060A2 (en) * | 2003-08-22 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating copd and pulmonary hypertension |
| BRPI0415896A (pt) * | 2003-10-28 | 2007-01-09 | Pharmacia Corp | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia |
-
2006
- 2006-03-14 EP EP06725042A patent/EP1865951A1/en not_active Withdrawn
- 2006-03-14 WO PCT/EP2006/060686 patent/WO2006097459A1/en not_active Application Discontinuation
- 2006-03-14 CA CA002600822A patent/CA2600822A1/en not_active Abandoned
- 2006-03-14 JP JP2008501286A patent/JP2008533090A/ja not_active Withdrawn
- 2006-03-14 US US11/885,836 patent/US20080171746A1/en not_active Abandoned
- 2006-03-14 AU AU2006224623A patent/AU2006224623A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008533090A5 (ja) | ||
| CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
| WO2009055721A3 (en) | 5-lipoxygenase activating protein (flap) inhibitor | |
| WO2008033455A3 (en) | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors | |
| WO2007096151A3 (en) | Inhibitors of p38-kinase for treatment of pulmonary hypertension | |
| WO2010032875A3 (en) | Heterocyclic carboxamide compounds | |
| WO2009030952A3 (en) | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| EA201000365A1 (ru) | Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза | |
| WO2008119685A3 (en) | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators | |
| MX2010001236A (es) | Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1). | |
| UA98757C2 (ru) | Бензамидные соединения, полезные как ингибиторы деацетилазы гистонов | |
| WO2008093075A3 (en) | 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors | |
| IL193252A0 (en) | N-hydroxyacrylamide compounds | |
| WO2010086860A3 (en) | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | |
| NO20076595L (no) | Behandling av leversykdommer hvor jern spiller en rolle i patogenesen | |
| JP2008534473A5 (ja) | ||
| MX2018009870A (es) | Inhibidores de taf1 para la terapia del cancer. | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
| AR062501A1 (es) | Composiciones terapeuticas | |
| WO2008080988A3 (en) | Cyclopentanone derivatives, method of synthesis and uses thereof | |
| WO2006108679A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer | |
| EA201600486A1 (ru) | Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид | |
| WO2019142053A3 (en) | Therapeutic inhibitory compounds | |
| WO2009041798A8 (es) | Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. |